127 results about "Alcohol intoxication" patented technology

The invention provides applications of levorotary oxiracetam and oxiracetam in preparing drugs for preventing or treating coma. Experimental results indicate that levorotary oxiracetam has obvious awaking effect on coma caused by alcoholism, but dextrorotary oxiracetam basically has no effect, and the awaking effect of levorotary oxiracetam is two times of that of dextrorotary / levorotary mixed oxiracetam; levorotary oxiracetam has remarkable awaking effect on comas caused by both trauma and anesthesia.

The invention relates to an alcohol-detoxication inflammation-relieving liver-protection beverage and a preparation method thereof. The beverage is prepared by taking radix puerariae, pueraria flower, citrus trifoliate, honeysuckle, chrysanthemum, rhizoma zingiberis recens and glucose as raw materials and refining and processing the raw materials by extraction technology. The beverage balances and integrates the functions of alcohol-detoxication, fever reduction, inflammation or internal heat relieving, and liver detoxification promotion, can effectively relieve bad symptoms of headache, thirst, excessive internal heat, gastric distress, and the like caused by alcoholism after a person drinks too excessively, and has obvious protection functions for livers. The invention can be prepared into liquid drink and solid drink as well.

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.

The invention discloses a weak alkali plant alcohol intoxication-alleviating beverage and a method for preparing the same. The beverage comprises the following components: plant extract, corrective, pH adjusting agent and pure water. The preparation method comprises the following steps that: firstly, the plant extract is decocted and filtered, and the obtained filtrate is cooled down to obtain the plant extract; secondly, the plant extract is mixed with the corrective, and the mixture is dissolved in water; and thirdly the mixed solution is added with proper amount of pH adjusting agent so as to adjust the pH value of the mixed solution to between 6.5 and 8.5, and the mixed solution is subjected to constant volume, filtering, homogenization, sterilization, filling, packaging and checking-up to obtain the weak alkali plant alcohol intoxication-alleviating beverage. The weak alkali plant alcohol intoxication-alleviating beverage has the advantages of removing alcohol toxins, alleviating the alcohol intoxication and protecting the liver, replenishing vital essence and clearing heat, promoting urination and releasing toxin and effectively preventing cardio-cerebral-vascular diseases, osteoporosis, gout, hypertension, high blood fat and the like, along with strong controllability of the production process, good quality reproductivity, fresh and good taste and the suitability for taking at four seasons.

The invention provides a functional product composition for sobering up and protecting the liver, comprising effective components and auxiliary materials which are acceptable in the medicine. The functional product composition for sobering up and protecting the liver is characterized in that the effective components are prepared by the following raw material medicines according to parts by weight: 5-60 parts of soybean protein, 4-50 parts of zein, 3-40 parts of ginseng, 2-40 parts of radix puerariae and 2-40 parts of raisin tree fruit. The composition can quickly lower the concentration of ethanol in blood after drinking, quickens the sobriety recovery of the brain and has very good functions of sobering up and restoring consciousness; the composition also can effectively treat acute alcoholism, prevents chronic alcoholism and lowers the injury of alcohol to liver cells.

The present invention relates to a method of treating alcoholism or alcohol abuse by administering to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking. Particularly, the present invention relates to a method of treating alcoholism or alcohol abuse by administering transmucosally to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking. Preferably, the opioid antagonist used in the method is nalmefene or a pharmaceutically acceptable salt thereof. The invention also relates to a method of treating alcoholism or alcohol abuse by administering to a subject before imminent drinking a transmucosal preparation comprising a pharmaceutically effective amount of an opioid antagonist, wherein the transmucosal preparation has rapid onset of action. Advantageously, a FAH+ subject is treated. Further, the invention relates to a method of treating alcoholism or alcohol abuse of a FAH+ subject, comprising extinguishing an alcohol-drinking response by administering to the FAH+ subject a pharmaceutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof.

The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs 1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.

Oligomers and polymer compositions are provided which comprise GHB and produce GHB after administration in vivo. Devices for the storage and delivery of these polymers and oligomers are also provided. These oligomers and polymer compositions are useful in a variety of applications. The compositions can be used therapeutically, for example, in the treatment of patients with narcolepsy, chronic schizophrenia, catatonic schizophrenia, atypical psychoses, chronic brain syndrome, neurosis, alcoholism, drug addiction and withdrawal, Parkinson's disease and other neuropharmacological illnesses, hypertension, ischemia, circulatory collapse, radiation exposure, cancer, and myocardial infarction. Other uses for the compositions include anesthesia induction, sedation, growth hormone production, heightened sexual desire, anorectic effects, euphoria, smooth muscle relaxation, muscle mass production, and sleep, including rapid eye movement sleep. In a still further embodiment, the oligomers and polymers may be used to produce absence seizures.

The invention relates to a composition with antialcoholism and hepatoprotective effect. The composition comprises flowers of kudzuvine, hovenia acerba, dandelion, licorice, dark plum, alanine, and glutamine in proportion, and can be processed to prepare various products with antialcoholism and hepatoprotective effect. The composition has the effects of improving human tolerance to alcohol, preventing acute alcoholism, assisting treatment of alcoholic hepatic injury, alcohol allergy, and the like. In addition, the invention also relates to a method for preparing various food and medicaments by the composition.

Methods / computer methods and systems / computer systems for the evaluation of two idiosyncratic indices of alcohol intoxication: the Alcohol Sensitivity Index (ASI), and the brain-specific Cognitive Alcohol Sensitivity Index (CASI). The two indices are based on the new Metabolic and Cognitive Minimal Models of Alcohol Dynamics, and are derived from specific clinical protocols, accompanied by specific data analysis procedures. The two indices may be derived from specific clinical and cognitive assessment protocols, accompanied by specific data analysis procedures based on the new metabolic and cognitive minimal models of alcohol dynamics.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

The invention provides an in vivo enzyme used for relieving alcoholism and a preparation method thereof. The in vivo enzyme comprises the following raw materials: prebiotics, dietary fiber, pueraria extract, hovenia acerba extract, turmeric extract, comprehensive garden stuff powder, probiotics, plant proteinase and a sweetening agent. The prebiotics includes inulin and functional oligosaccharide.The in vivo enzyme used for relieving alcoholism is capable of protecting liver after drinking, can play a role in drinking stage, alcohol absorbing stage and all the stages of alcohol metabolism, and can prevent or relieve alcoholism. A dry mixing process is preferably adopted by the preparation technology of the invention; probiotics having different characteristics, prebiotics and plant proteinase from different nutrient sources are optimally combined with each other so as to produce the in vivo enzyme used for relieving alcoholism of consumers of different genders; the problem that the present enzyme product only sells concept and has no obvious effect can be solved.

The gene (SLC6A4) responsible for encoding the serotonin transporter (SERT) has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on diagnosing variations in the polymorphisms of the SERT gene and expression and activity of the SERT gene, as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders, for monitoring treatment and / or abuse (addictive behavior), and for determining which treatment should be used.

Soluble complexes of flumazenil, methods for the preparation thereof, pharmaceutical compositions including same and use of the compositions for alleviating or counteracting the various types of hypersomnia, drowsiness, residual effects associated with the administration of sleep / hypnotic drugs, alcohol intoxication or hepatic encephalopathy.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

The invention provides a crab apple extract, application of the extract in preparing a hepatic or health-care food and a pharmaceutical composition containing the crab apple extract. The medicament belongs to a pure natural preparation, is not subjected to organic dissolution treatment, and is safe and reliable; the medicament is developed from food, has small toxicity, and has no adverse reactionafter being used for a long time; the medicament can be drunk as tea, and has convenient use and delicious taste; the medicament has protection effect on hepatic injury caused by various reasons, andhas prevention and treatment effects on various diseases caused by the hepatic injury; and the medicament has good effect on treating or preventing acute alcoholism, and can obviously improve varioussymptoms caused by alcoholic intoxication such as dizziness, headache, hypodynamia and the like.

Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Abstinence from alcohol consumption may be maintained using ibudilast or a pharmaceutically acceptable salt thereof. Withdrawal from alcohol may be facilitated and negative effects thereof reduced by using ibudilast or a pharmaceutically acceptable salt thereof.

The invention discloses a preparation method of decanting and liver-protecting hawthorn beverage for producing acetaldehyde dehydrogenase through co-fermentation of lactobacillus. The method comprises the following steps: by adopting hawthorn as a raw material, squeezing and carrying out biological enzymolysis and clarifying; carrying out lactobacillus complex fermentation through controlling the ratio and the fermentation temperature and time of lactobacillus acidophilus and lactobacillus plantarum to obtain the novel fermented decanting and liver-protecting hawthorn beverage which is abundant in nutrient and unique in flavor and taste. The original efficacy of the hawthorn is reserved, the content of live bacteria of lactic acid bacteria is greater than 106 per mL, the lactic acid content is greater than 0.5%, the content of the acetaldehyde dehydrogenase is greater than 2U / 100mL, and the hawthorn beverage has decanting and liver-protecting effects and has a unique flavor. The beverage has the decanting, liver-protecting hawthorn and anti-intoxitation effects, is capable of effectively increasing the tolerance dose on ethyl alcohol when the beverage is drunk before drinking or while drinking, is capable of relieving or eliminating the drunkenness symptom when the beverage is drunk after drinking, and has good decanting and liver-protecting effects on alcoholism patients.

In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention combines the use of an opioid antagonist with at least one dopamine D2 partial agonist for the treatment of alcoholism. Suitable dopamine D2 partial agonists are aripiprazole and (−)3-(3-hydroxyphenyl)-N-n-propylpiperidine [(−)-3PPP].

The invention discloses a natural component extract enriched alcohol effect dispelling liver-protection drink and a preparation method thereof. The natural component extract enriched alcohol effect dispelling liver-protection drink comprises the following substances: a kudzu vine root extract, a schisandra chinensis extract, a turnjujube extract, a loquat leaf extract, a poria cocos extract, a cranberry extract, a mulberry extract, a mung bean extract, a chrysanthemum extract, a banana extract, ginger juice, watermelon juice, tomato juice, grape juice, honey, distilled water, methylparaben and 75% ethanol. Compared with the prior art, the natural component extract enriched alcohol effect dispelling liver-protection drink disclosed by the invention has effects of alcohol effect dispelling liver protection, is light brown and is sour and sweet, alcohol absorption can be reduced, alcohol metabolism can be accelerated, drunkenness can be prevented if the drink is taken before wine drinking, the drunkenness time can be shortened if the drink is take after wine drinking, various body discomfort symptoms caused by alcohol can be alleviated, liver injury caused by alcohol can be alleviated, the alcohol effect can be dispelled, the mind can be refreshed, livers can be protected, hearts can be calmed, alcoholism or drunkenness can be rapidly alleviated, and wide application prospects can be achieved.

Accurate self report strategies, biological state markers, combinations of alternative biomarkers, and combinations of biomarkers and self reports capable of monitoring alcohol consumption with a high sensitivity and specificity over a broad time spectrum are disclosed. In particular, the use of ethyl sulfate (monoethylsulfate, molecular weight 126 g / mol, C2H5SO4H) to elucidate ethanol intake is described in the context of screening monitoring in various settings, e.g. a) after liver transplantation b) methadone maintenance patients with hepatitis C and comorbid excessive alcohol use c) underage drinking d) rehabilitation programs for alcoholics motivational feedback to improve knowledge on drinking patterns differentiating moderate / social drinking from problematic / harmful drinking differential diagnosis (e.g. elevated transaminases) evaluating treatment programs and drug trials elucidating the role of neuropsychological impairment following alcoholisation (i.e. hangover state) which plays a major role in accidents, disclosing recent drinking in social drinkers in risky situations (driving, workplaces, pregnancy (fetal alcohol syndrome (FAS)), and general monitoring.

The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases such as novelty-seeking character, alcoholism, anxiety and emotion disorder by stress, etc. The α1G T-type channel transgenic mice showing novelty-seeking and alcohol preference of the present invention can be effectively used for the development of a medicine and a therapeutic method for human nervous diseases.

Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug / alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.

The present invention provides methods for reducing alcohol drinking behavior in humans and treating acute alcohol poisoning through the use of neutral or negative modulating agents of the neurosteroid sites on GABAA receptors. These agents avoid the unwanted side-effects of opiate antagonists and displays specificity toward the neurosteroid binding sites on GABAA receptors.

The present invention relates to compositions and methods for determining whether an individual is predisposed to or protected from alcoholism. In particular, the present invention provides genetic markers useful for the diagnosis, characterization, and treatment or prevention of alcohol tolerance, abuse and / or dependence.

The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and / or neuronal death and / or glucose impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

A new class of high water-soluble compound based upon the Hovenia plant, or its herbal extract form known as DHM, and the methods for synthesizing same, to produce anti-alcohol intoxication treatment to alleviate the symptoms of hangover and other over-drinking, binge-drinking related ailments. Such compounds, known as TDHM and PDHM, can reduce the alcohol concentration in the blood, lengthen the waking time, and shorten the period of drowsiness induced after drinking alcohol; they also are proved to have high water solubility and thus are suitable for immediate protection and treatment to persons with alcohol intoxication or hangover and over-drinking.

The present invention relates to novel biologically active compounds, in particular dicarboxylic acid bisamide derivatives of general formula I:or pharmaceutically acceptable salts thereof, which are able to form complexes with or chelate metal ions. The invention also relates to the use of said compounds as an agent for the prevention and / or treatment of cardiovascular, viral, cancer, neurodegenerative and inflammatory diseases, diabetes, age-related diseases, diseases caused by microbial toxins, alcoholism and alcoholic cirrhosis, anaemia, porphyria cutanea tarda, and transition metal salt poisoning. The present invention also relates to novel methods for preparing dicarboxylic acid bisamide derivatives of general formula I.